Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sesen Bio Inc (SESN)

Sesen Bio Inc (SESN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,500
  • Shares Outstanding, K 110,416
  • Annual Sales, $ 0 K
  • Annual Income, $ -107,500 K
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.17
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.10
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6900 +3.43%
on 06/30/20
0.8000 -10.79%
on 06/10/20
-0.0881 (-10.99%)
since 06/01/20
3-Month
0.5000 +42.74%
on 04/03/20
0.9450 -24.48%
on 05/08/20
+0.1521 (+27.08%)
since 04/01/20
52-Week
0.3700 +92.89%
on 03/17/20
1.5400 -53.66%
on 10/28/19
-0.7963 (-52.74%)
since 07/01/19

Most Recent Stories

More News
Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium(R)

Sesen Bio (Nasdaq: SESN) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow, chief...

TRVN : 1.5800 (+5.33%)
SESN : 0.7137 (-0.88%)
Growing Global Demand for Non-Invasive Cellulite Treatment with FDA Clearance

Cellulite affects 85% to 90% of all women worldwide and was first described nearly 100 years ago, and has been the bane of women (and men) ever since. But to find a 'cure' or effective 'solution' the cause...

SOLY : 7.67 (-1.41%)
BSX : 35.28 (+0.48%)
SWAV : 46.88 (-1.03%)
SESN : 0.7137 (-0.88%)
PFE : 33.74 (+3.18%)
Options Traders Expect Huge Moves in Sesen Bio (SESN) Stock

Sesen Bio (SESN) needs investors to pay close attention to the stock based on moves in the options market lately.

SESN : 0.7137 (-0.88%)
Positive Results and New Technology Give Rise to Antibody Dominance

Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market...

IPA.VN : 1.660 (-6.74%)
IPATF : 1.3000 (+6.56%)
ZYME : 36.37 (+0.83%)
ZYME.TO : 33.10 (+1.63%)
SESN : 0.7137 (-0.88%)
PMN.TO : 0.22 (+4.76%)
ARFXF : 0.1585 (+0.19%)
Demand for Cancer Treatment Remains High Despite Improving Survivability Rates

Deaths related to cancer dropped by 27% in the past quarter-century, meaning that 2.6 million fewer people died due to cancer during that time period, according to a report by the American Cancer Society....

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
SESN : 0.7137 (-0.88%)
CGIX : 2.83 (-6.60%)
ABIO : 6.71 (+1.36%)
NAVB : 4.07 (+3.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade SESN with:

Business Summary

Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven...

See More

Key Turning Points

2nd Resistance Point 0.7379
1st Resistance Point 0.7258
Last Price 0.7137
1st Support Level 0.7008
2nd Support Level 0.6879

See More

52-Week High 1.5400
Fibonacci 61.8% 1.0931
Fibonacci 50% 0.9550
Fibonacci 38.2% 0.8169
Last Price 0.7137
52-Week Low 0.3700

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar